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Tigecycline has an extended spectrum of in vitro antimicrobial activities, including that against multidrug-
resistant Acinetobacter. After identifying bloodstream isolates of Acinetobacter with reduced susceptibilities to
tigecycline, we performed a study to assess tigecycline efflux mediated by the resistance-nodulation-division-
type transporter AdeABC. After exposure of two tigecycline-nonsusceptible isolates to the efflux pump inhibitor
phenyl-arginine--naphthylamide (PABN), a fourfold reduction in the tigecycline MIC was observed. Both
tigecycline-susceptible and -nonsusceptible isolates were found to carry the gene coding for the transmembrane
component of the AdeABC pump, adeB, and the two-component regulatory system comprising adeS and adeR.
Previously unreported point mutations were identified in the regulatory system in tigecycline-nonsusceptible
isolates. Real-time PCR identified 40-fold and 54-fold increases in adeB expression in the two tigecycline-
nonsusceptible isolates compared to that in a tigecycline-susceptible isolate. In vitro exposure of a tigecycline-
susceptible clinical strain to tigecycline caused a rapid rise in the MIC of tigecycline from 2 g/ml to 24 g/ml,
which was reversible with PABN. A 25-fold increase in adeB expression was observed in a comparison between
this tigecycline-susceptible isolate and its isogenic tigecycline-nonsusceptible mutant. These results indicate
that an efflux-based mechanism plays a role in reduced tigecycline susceptibility in Acinetobacter.
Tigecycline is the first of a new class of modified tetracycline
antimicrobials known as glycylcyclines. Its structural modifica-
tion is the addition of a 9-t-butyl-glycylamido side chain to the
central skeleton of minocycline (16). This provides the drug
with an expanded spectrum of activities, including those
against susceptible and multidrug-resistant gram-positive and
-negative organisms, anaerobes, and atypical pathogens. As
with other tetracycline derivatives, tigecycline inhibits the 30S
ribosomal subunit, but its unique feature is its ability to evade
the major determinants of tetracycline resistance, the tet(A) to
tet(E) and tet(K) efflux pumps and the tet(M) and tet(O) de-
terminants, that provide ribosomal protection (3). Despite this,
tigecycline has poor activities against certain organisms, most
importantly Pseudomonas spp. and Proteus spp. Previous stud-
ies have shown that the reduced tigecycline susceptibilities of
such organisms are due to chromosomally encoded multidrug
efflux pumps from the resistance-nodulation-division (RND)
family, specifically the MexXY-OprM pump in Pseudomonas
aeruginosa and the AcrAB efflux pump in Proteus mirabilis (2,
22). Also, reduced tigecycline susceptibility in Escherichia coli
and Klebsiella pneumoniae has recently been attributed to the
up-regulation of the multidrug efflux pump AcrAB (6, 19).
RND-type efflux pumps are tripartite structures that include an
inner membrane transporter, an outer membrane channel, and
a membrane fusion protein (17, 18). Such pumps are of par-
ticular concern given their wide substrate profiles and their
abilities to be selected after exposure to a single antimicrobial
agent.
Acinetobacter is a ubiquitous, gram-negative coccobacillus
that has emerged as a highly problematic hospital-associated
pathogen (13). Its spectrum of illness is wide and includes
pneumonia, bloodstream infection, urinary tract infection, skin
and wound infection, meningitis, and endocarditis (14), with
the distribution of these dependent on the reporting institu-
tion. Apart from its resilience in the environment, Acineto-
bacter is characterized by its ability to rapidly acquire resistance
determinants, with enzymatic mechanisms predominating (1).
More recently, the role of a multidrug efflux pump in Acineto-
bacter drug resistance, namely, AdeABC, has been described
(9, 10). Of interest, this efflux pump belongs to the RND family
and has a similar three-component structure: AdeB forms the
trans-membrane component, AdeA forms the inner membrane
fusion protein, and AdeC forms the outer membrane protein.
AdeABC is chromosomally encoded and is regulated by a
two-component system comprising a sensor kinase (AdeS) and
its associated response regulator (AdeR) (10). Point mutations
in such components have been associated with overexpression
of AdeABC leading to multidrug resistance (10). The substrate
profile for the AdeABC efflux pump is broad, including tetra-
cyclines, aminoglycosides, fluoroquinolones, chloramphenicol,
and some -lactams (9).
We have recently managed two patients with bloodstream
infections caused by tigecycline-nonsusceptible Acinetobacter
baumannii (15). Given the mechanism of reduced tigecycline
susceptibility in Pseudomonas spp. and Enterobacteriaceae and
the similarity between RND-type efflux pumps, we investigated
the role of efflux as a cause of tigecycline nonsusceptibility in
Acinetobacter.
MATERIALS AND METHODS
Bacterial strains. The bacterial strains included in this study were as follows:
three clinical isolates (A24, B46, and C75) that were obtained from separate
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patients with bloodstream infections due to A. baumannii at the University of
Pittsburgh Medical Center, PA, two isolates (B46 and C75) cultured from pa-
tients who were receiving intravenous tigecycline for other indications at the time
of isolation (15), and a tigecycline-susceptible laboratory strain (D54) known to
carry the adeB gene and the two-component regulatory system comprising adeR
and adeS, which was studied for comparative analysis. The strains were cultivated
in Luria-Bertani (LB) broth.
Antimicrobial susceptibility testing. Tigecycline MICs were initially deter-
mined by the Etest method (AB Biodisk, Solna, Sweden) and confirmed by agar
dilution using Mueller-Hinton II agar (Oxoid, Hampshire, England). Suscepti-
bility testing of other antimicrobials was performed by broth microdilution (9).
Bacterial cultures were prepared fresh on the day of testing. Tigecycline (Wyeth,
Madison, NJ) powder was obtained from commercial sources and was prepared
in a solution by using sterile water, and the solution was then frozen in aliquots
at 80°C. Currently, the U.S. FDA and EUCAST have defined susceptibility
breakpoints for tigecycline only for Enterobacteriaceae (2 g/ml and 1 g/ml,
respectively). Neither CLSI nor BSAC have provided breakpoints for tigecycline.
For the purposes of this study, we have defined susceptibility as a MIC of2 g/ml
for Acinetobacter.
Tigecycline in vitro exposure. To assess whether tigecycline nonsusceptibility
in Acinetobacter occurs after tigecycline exposure and whether this resistance is
reversible with an efflux pump inhibitor, we performed an in vitro exposure
experiment. Fresh cultures underwent serial overnight exposure to tigecycline,
starting at a tigecycline concentration of half the MIC and doubling the exposure
concentration each 24 h until there was no growth. Exposure was performed with
fresh Mueller-Hinton II agar that had been boiled before bacterial and antibiotic
inoculation to prevent oxidative degradation of tigecycline (7). A 0.5 McFarland
inoculum was used, and MICs were recorded daily. Bacteria from the final day
of growth underwent exposure to the efflux pump inhibitor phenyl-arginine--
naphthylamide (PABN) (11), and tigecycline MIC determinations were re-
peated. PABN powder was resuspended in pure water to a 25 mg/ml concentra-
tion and then added to 250 ml of Mueller-Hinton agar cooled to 50°C. Genomic
DNA from the final day’s growth was also analyzed by pulsed-field gel electro-
phoresis (PFGE) and compared to that for the parent strain to confirm isoge-
nicity. An isogenic mutant was selected to undergo comparative assessment of
adeB gene expression by real-time PCR (RT-PCR).
Accumulation of ethidium bromide. A functional efflux pump assessment was
performed by measuring the accumulation of ethidium bromide before and after
exposure to carbonyl cyanide m-chlorophenylhydrazone (CCCP), a protono-
phore that disrupts membrane proton force. The method was slightly modified
from that described previously (4, 9). Briefly, cells were grown overnight, pel-
leted, and resuspended to an A600 of 0.2 in sodium phosphate buffer (pH 7.0).
Ethidium bromide was added to the suspension at a final concentration of 2
g/ml. Ethidium bromide accumulation, which is inversely proportional to the
activity of the efflux pump, was recorded by the fluorescence intensity (excite, 530
nm; emit, 600 nm) on a SpectraMax M2 spectrofluorometer (Molecular Devices
Corporation, Sunnyvale, CA). The bacterial cells were initially incubated with
ethidium bromide for 420 s. Following this, CCCP was added at a final concen-
tration of 100 M and incubated for a further 180 s. Background fluorescence
from bacterial cells alone was subtracted. The results were expressed as percent
increases in ethidium accumulation after CCCP exposure.
PCR and nucleotide sequencing. The primers specific for the genes encoding
the two-component regulatory system comprising adeS and adeR and the trans-
membrane component adeB are shown in Table 1. PCR amplification was per-
formed using a 9700 GeneAmp thermocycler (Applied Biosystems, Foster City,
CA). PCRs for adeR and adeS were as described previously (8), except a primer
annealing temperature of 50C was used for adeS. For adeB, a similar cycling
program was used and ran for 40 cycles with an annealing temperature of 60°C.
Sequencing of the products was performed by an ABI 3730 DNA analyzer
(Applied Biosystems) and then analyzed using Lasergene DNAStar sequencing
software (DNAStar, Madison, WI).
RT-PCR. adeB gene expression was measured using RT-PCR. Bacterial cells
were grown aerobically in LB broth until mid-log phase. DNase-treated RNA
templates were prepared using an RNeasy kit (QIAGEN Sciences, MD). The
concentrations of the RNA were quantified with a spectrophotometer. Oligonu-
cleotide primers for the adeB gene were designed using Primer Express version
2 (Applied Biosystems) and purchased from IDT DNA (Coralville, IA) (Table
1). 16S RNA was used as a housekeeping gene to normalize levels of adeB
transcripts. Reverse transcription was performed using a high-capacity cDNA
archive kit (Applied Biosystems) with 350 ng of RNA in a 50-l reaction mixture
containing 1 (each) reverse transcription buffer, deoxynucleoside triphosphate
mix, and random primers as well as 2.5 U/ml multiscribe reverse transcriptase.
Negative-control reactions included equal concentrations of RNA and all re-
agents except reverse transcriptase, which was omitted. Incubation for 10 min at
25°C followed by 2 h at 37°C was carried out with a Tetrad DNA engine (MJ
Research). RT-PCR was performed with a 7900HT sequence detection system
(Applied Biosystems) with SYBR green PCR master mix (Applied Biosystems)
at a 1 concentration containing 125 nM of each primer and a 1:100 final
dilution of the cDNA product. The Taq activation step of 12 min at 95°C was
followed by 40 cycles of 15 seconds at 95°C and 1 min at 60°C. Following PCR
cycling, melting point data were collected and a dissociation curve was examined
for each well. Each sample was run in triplicate. The critical threshold cycle (CT)
numbers were determined by Sequence Detection Systems version 2.2.2 (Ap-
plied Biosystems). The CT for adeB was calculated against that for the 16S
RNA housekeeping gene, and the CT was calculated against that for the
tigecycline-susceptible calibrator sample (D54).
PFGE. Chromosomal DNA was incubated and digested by ApaI (New En-
gland Biolabs, Beverly, MA). The restriction fragments were separated by PFGE
using a temperature-controlled CHEF DR III system (Bio-Rad) as described
previously (20). The fragments were visualized by using a Bio-Rad Gel Doc 2000
system. For PFGE pattern analysis, Bionumerics software version 4.0 with the
unweighted-pair group method using average linkages and the DICE setting for
clustering analysis (Applied Maths, Sint-Martens-Latem, Belgium) was applied.
The genetic relatedness of isolates was determined by the criteria of Tenover
et al. (21).
Nucleotide sequence accession numbers. The GenBank accession numbers for
the nucleotide sequences determined and reported in this study are EF520299,
EF520297, EF520296, and EF520298 for adeS of A24, B46, C75, and D54,
respectively, and EF520294, EF520292, EF520291, and EF520293 for adeR of
A24, B46, C75, and D54, respectively.
TABLE 1. Primer sequences used for this study
Gene Primer sequence Source or reference
adeR Forward, 5	-ATGTTTGATCATTCTTTTTCTTTTG-3	 8
Reverse, 5	-TTAATTAACATTTGAAATATG-3	
adeS Forward, 5	-ATGAAAAGTAAGTTAGGAATTAGTAAG-3	 This study
Reverse, 5	-TTAGTTATTCATAGAAATTTTTATG-3	
adeB (qualitative) Forward, 5	-GTATGAATTGATGCTGC-3	 9
Reverse, 5	-CACTCGTAGCCAATACC-3	
adeB (quantitative) Forward, 5	-AACGGACGACCATCTTTGAGTATT-3	 This study
Reverse, 5	-CAGTTGTTCCATTTCACGCATT-3	
16S RNA Forward, 5	-CAGCTCGTGTCGTGAGATGT-3	 5
Reverse, 5	-CGTAAGGGCCATGATGACTT-3	
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RESULTS AND DISCUSSION
Susceptibility profiles of bacterial strains. The susceptibility
profiles of the bacterial strains are shown in Table 2. All clin-
ical isolates were resistant to multiple antimicrobial agents,
including aminoglycosides, ciprofloxacin, chloramphenicol, and
certain -lactams. The laboratory strain (D54) was susceptible
to all tested antimicrobials, including tigecycline (MIC, 0.125
g/ml). The tigecycline MICs were 2 g/ml, 4 g/ml, and 16
g/ml for isolates A24, B46, and C75, respectively. After ex-
posure of the tigecycline-nonsusceptible clinical isolates (B46
and C75) to the efflux pump inhibitor PABN, the tigecycline
MICs were reduced to 1 g/ml and 4 g/ml, respectively. Also,
reductions in the MICs of gentamicin, tobramycin, chloram-
phenicol, and -lactams were observed (Table 2). PABN had
no effect on the MIC of tigecycline for the tigecycline-suscep-
tible clinical strain (A24). All four isolates were genetically
unrelated (data not shown). Such results support the existence
of a multidrug efflux pump but are nonspecific with regard to
the type of pump involved and the mechanism of increased
pump activity.
Tigecycline in vitro exposure. To provide supporting evi-
dence, we performed an in vitro tigecycline exposure experi-
ment using a tigecycline-susceptible clinical isolate (A24). Af-
ter exposure of A24 (MIC, 2 g/ml) to serially increasing
concentrations of tigecycline, starting at 1 g/ml and doubling
each day, the MICs were 2 g/ml (A24A), 2 g/ml (A24B), 6
g/ml (A24C), and 24 g/ml (A24D) on days 1, 2, 3, and 4,
respectively. The MICs for other antimicrobials, including
minocycline, gentamicin, tobramycin, chloramphenicol, and -
lactams, were also increased. To assess whether the rise in
tigecycline MIC was a result of an efflux-based mechanism,
A24D was exposed to PABN. The tigecycline MIC was re-
duced to the level of the parent strain (2 g/ml). PABN expo-
sure also reduced the MICs for other antimicrobials (Table 2).
PFGE of the above-mentioned isolates confirmed isogenicity
(data not shown). These results strongly support the theory
that tigecycline nonsusceptibility in A. baumannii is due to a
multidrug efflux pump. Given that tigecycline exposure may
increase the activities of many pumps and that PABN is a
nonspecific efflux pump inhibitor, this experiment does not
clarify the type of pump involved. The increase in the MIC of
tigecycline during the in vitro exposure experiment supports a
hypothesis for a two-step mutation process; however, this re-
quires further investigation.
Accumulation of ethidium bromide. To further assess the
role of an efflux-based mechanism in reduced tigecycline sus-
ceptibility in Acinetobacter, we performed a functional experi-
ment of efflux pump activity using ethidium bromide accumu-
lation (inversely proportional to pump activity). RND-type
pumps mediate the efflux of toxic compounds by using the
proton gradient across the membrane, exchanging one H ion
for one drug molecule (12). CCCP disrupts this proton gradi-
ent and therefore inhibits pump activity, resulting in a rise in
ethidium bromide accumulation. The results are expressed as
percent increases in ethidium bromide accumulation after
CCCP exposure and are presented in Fig. 1. Both the tigecy-
cline-susceptible clinical (A24) and the laboratory (D54)
strains showed lower increases in ethidium bromide accumu-
lation after the addition of CCCP (52% and 31%, respectively)
than the tigecycline-nonsusceptible clinical strains (B46 and
C75) (115% and 206% increases, respectively). Similarly, the
TABLE 2. Susceptibility profiles of the bacterial strains included in this studya
Strain
MIC (g/ml) (susceptibility rating) for indicated drug
TGC MIN GEN TOB CIP CHL PIP CAZ FEP IPM MEM
D54 0.125 0.125 (S) 0.25 (S) 0.75 (S) 0.25 (S) 0.125 (S) 16 (S) 4.0 (S) 1.5 (S) 0.125 (S) 0.25 (S)
A24 2.0 32 (R) 64 (R) 4.0 (S) 256 (R) 16 (I) 16 (S) 
256 (R) 16 (I) 0.38 (S) 1.0 (S)
A24  PABN 2.0 2.0 (S) 48 (R) 3.0 (S) 128 (R) 12 (I) 3.0 (S) 96 (R) 3.0 (S) 0.032 (S) 0.094 (S)
A24A 2.0 12 (I) 256 (R) 3.0 (S) 256 (R) 96 (R) 12 (S) 
256 (R) 12 (I) 0.125 (S) 0.75 (S)
A24B 2.0 16 (R) 256 (R) 4.0 (S) 256 (R) 96 (R) 12 (S) 
256 (R) 12 (I) 0.125 (S) 0.75 (S)
A24C 6.0 16 (R) 512 (R) 6.0 (I) 256 (R) 96 (R) 16 (S) 
256 (R) 16 (I) 0.19 (S) 0.75 (S)
A24Db 24 32 (R) 256 (R) 16 (R) 512 (R) 16 (I) 24 (I) 
256 (R) 16 (I) 0.50 (S) 2.0 (S)
A24D  PABN 2.0 8.0 (I) 96 (R) 8.0 (I) 128 (R) 4.0 (S) 1.0 (S) 32 (R) 1.0 (S) 0.064 (S) 0.094 (S)
B46 4.0 0.25 (S) 8.0 (I) 24 (R) 128 (R) 32 (R) 256 (R) 96 (R) 
256 (R) 1.5 (S) 4.0 (I)
B46  PABN 1.0 0.25 (S) 4.0 (S) 16 (R) 128 (R) 8.0 (S) 256 (R) 8.0 (S) 128 (R) 0.25 (S) 0.25 (S)
C75 16 2.0 (S) 128 (R) 16 (R) 512 (R) 32 (R) 48 (I) 192 (R) 
256 (R) 1.5 (S) 4.0 (I)
C75  PABN 4.0 1.0 (S) 16 (R) 6.0 (I) 256 (R) 8.0 (S) 8.0 (S) 8.0 (S) 16 (I) 0.125 (S) 0.125 (S)
a TGC, tigecycline; MIN, minocycline; GEN, gentamicin; TOB, tobramycin; CIP, ciprofloxacin; CHL, chloramphenicol; PIP, piperacillin; CAZ, ceftazidime; FEP,
cefepime; IPM, imipenem; MEM, meropenem; R, resistant; S, susceptible; I, intermediate.
b An isolate that underwent tigecycline in vitro exposure.
FIG. 1. Percent increases in ethidium bromide accumulation after
exposure to CCCP, a protonophore that disrupts membrane active
transport, in two tigecycline-nonsusceptible clinical isolates (B46 and
C75), a tigecycline-susceptible clinical isolate (A24), its tigecycline-
nonsusceptible isogenic mutant (A24D), and a tigecycline-susceptible
laboratory strain (D54). Error bars represent standard errors.
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strain that developed tigecycline resistance after in vitro tige-
cycline exposure (A24D) showed a 114% increase in ethidium
bromide accumulation after CCCP addition.
Analysis of adeB expression. The gene adeB codes for the
transmembrane protein of the AdeABC multidrug efflux
pump. All isolates in the present study were found to carry the
adeB gene. As described by Magnet et al., disruption of this
gene leads to the loss of multidrug resistance (9). Because of its
necessity for AdeABC function, we investigated its expression
in a range of isolates with various tigecycline MICs using RT-
PCR. We first compared adeB expression in tigecycline-non-
susceptible clinical isolates (C75 and B46) with that in our
tigecycline-susceptible laboratory strain (D54). Approximate
40-fold and 54-fold increases in adeB expression were ob-
served, respectively (Fig. 2). In contrast, only a fourfold in-
crease in adeB expression was seen with the tigecycline-suscep-
tible clinical strain (A24). We then compared adeB expression
in our tigecycline-susceptible clinical strain (A24) and its iso-
genic tigecycline-nonsusceptible mutant (A24D). A 25-fold in-
crease in adeB expression was observed, which equated to a
100-fold increase compared to the level in the tigecycline-
susceptible laboratory strain (D54). These data support the
hypothesis that increased expression of adeB is associated with
increased MICs of tigecycline. However, in the absence of an
adeB gene knockout experiment, the overall contribution of
the AdeABC efflux pump to tigecycline nonsusceptibility can-
not be ascertained. This is an important limitation of the cur-
rent study, as the phenotype may well be explained by in-
creased expression in another efflux system. Further research
activities are focused on this area.
Nucleotide sequencing of the AdeABC regulatory system. To
further assess the mechanism of increased adeB expression,
mutations in the two-component regulatory system of the
AdeABC efflux pump comprising adeR and adeS were inves-
tigated. All isolates in the present study were found to carry
adeR and adeS. Point mutations in adeR (Pro1163Leu) and
adeS (Thr1533Met) known to cause AdeABC overexpression
(10) were not identified in any of our included isolates. The
adeR and adeS sequences of the isolates included in this study,
as well as a previously sequenced Acinetobacter baumannii
clinical isolate found to have overexpression of the AdeABC
pump (BM4454) (9, 10), were compared (Table 3). There were
no point mutations found only in the tigecycline-nonsuscep-
tible isolates (B46 and C75) and BM4454 compared with the
tigecycline-susceptible isolates (D54 and A24). The tigecy-
cline-susceptible clinical isolate (A24) had six point mutations
compared with the tigecycline-susceptible laboratory isolate
(D54), whereas the two tigecycline-nonsusceptible clinical iso-
lates (B46 and C75) had eight point mutations. When the
sequences of the tigecycline-susceptible clinical isolate (A24)
were compared to those of its tigecycline in vitro-exposed in-
termediates (A24A, B, and C) and a final mutant (A24D), no
change in sequences was observed (data not shown). It is
possible that multiple point mutations in the two-component
regulatory system of AdeABC may lead to pump overexpres-
sion. However, the lack of mutations in A24D compared to its
isogenic parent strain (A24), despite increases in MICs of
tigecycline and in adeB gene expression, indicates that other
mechanisms for increased pump activity are also involved. It
has previously been suggested that amino acid substitutions in
an efflux pump protein are able to make it more efficient at
export (17); however, this would not explain an increase in
adeB gene expression.
Acinetobacter is proving to be a highly resilient and adapt-
able microorganism that has the capacity to cause problematic
outbreaks in health care institutions (13, 14). The organism has
an ever-increasing list of resistance determinants that can rap-
idly nullify most of our therapeutic armamentarium. Thus far,
enzymatic mechanisms of resistance, including a wide array of
-lactamases and aminoglycoside-modifying enzymes, have
predominated (1). More recently, the roles of multidrug ef-
FIG. 2. Expression of adeB mRNA transcripts as assessed by RT-
PCR. The relative quantification of adeB expression in the tigecycline-
nonsusceptible clinical isolates (B46 and C75), the tigecycline in vitro-
exposed isolate (A24D), and its isogenic parent strain (A24) compared
to that in the reference tigecycline-susceptible laboratory strain (D54)
is shown. Error bars represent standard errors.
TABLE 3. Differences between the amino acid sequences of the adeR and adeS gene products for the indicated strainsa
Strain
Amino acid at indicated position of protein encoded by indicated gene
adeR adeS
120 142 158 59 60 186 227 245 279 293 327
D54 V I H V D G D I A S V
A24 I L H V D V D V V G V
B46 I L L I D G H V A G E
C75 I L L I Y G H V A G V
BM4454 I L H V D V D V V G V
a The strains used were a tigecycline-susceptible laboratory strain (D54), a clinical strain (A24), two tigecycline-nonsusceptible clinical strains (B46 and C75), and
a previously sequenced Acinetobacter baumannii isolate found to have overexpression of the AdeABC pump (BM4454) (9, 10). V, valine; A, alanine; I, isoleucine; D,
aspartic acid; Y, tyrosine; G, glycine; H, histidine; L, leucine; S, serine; and E, glutamic acid.
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flux pumps have been described, particularly that of the
RND-type pump AdeABC (5, 9, 10). Our results indicate
that an efflux-based mechanism plays a role in reduced tige-
cycline susceptibility in Acinetobacter. The contribution of
the AdeABC pump compared to those of other efflux sys-
tems is yet to be confirmed; however, given the increased
adeB gene expression in tigecycline-nonsusceptible strains,
this pump is at least partly involved. This is the first descrip-
tion, to our knowledge, of the proposed mechanism of tige-
cycline nonsusceptibility in Acinetobacter. The ability of
Acinetobacter to rapidly acquire resistance to this new gly-
cylcycline antimicrobial is cause for concern and adds fur-
ther stimulus for the discovery of newer antimicrobials with
activities against this problematic organism.
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